Rubén Silva-Tinoco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rubén Silva-Tinoco has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
Teresa Cuatecontzi-Xochitiotzi
10 shared publicationsLilia Castillo-Martínez
9 shared publications- Lilia Castillo-Martínez
Department of Clinical Nutrition, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
9 shared publications Arturo Orea-Tejeda
Former Head, Cardiology Service, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico
8 shared publicationsEnrique León-García
Servicios de Salud Pública del Gobierno de la Ciudad de México, Mexico City, Mexico
7 shared publicationsJavier Serna-Alvarado
Servicios de Salud Pública del Gobierno de la Ciudad de México, Mexico City, Mexico
7 shared publications
Latest Publications
- Open Access
- 27 August 2026
- Published by SAGE Publications in Health Services Insights
- Vol. 19
Integrative Monitoring of Hypertension Care Using Routinely Collected Clinical Data in Mexico’s Emerging Federalised Public Health Care Provider
Background: Health information systems are a cornerstone for assessing health system performance, particularly for leading conditions contributing to disease burden, such as hypertension, making effective monitoring indispensable. In October 2023, Mexico initiated the federalisation of public health services for the population without social security, creating an integrated national public health care provider and increasing the need for system-level monitoring tools capable of supporting longitudinal assessment across heterogeneous settings. Objective: To describe the development and early application of an integrative monitoring platform using routinely collected clinical data to support system-level oversight of hypertension care within Mexico’s federalised public health care provider. Design: Descriptive health services research study based on secondary analysis of routinely collected clinical data. Methods: An integrative monitoring platform was developed to organise data into a structured indicator framework covering four domains: care engagement and continuity; clinical care processes; intermediate clinical outcomes; and case-mix and clinical complexity. The platform enables longitudinal and subnational analyses across selected indicators presented as illustrative use cases. Institutional reach was assessed using an overall monitoring period from January 2024 to September 2025, while clinical process and intermediate outcome indicators, including blood pressure control, were calculated within a predefined active six-month monitoring cohort using the September 2025 reporting date. Results: From January 2024 to September 2025, a total of 486,044 individuals received hypertension-related care within primary care services across participating states. The active six-month cohort included 322,661 individuals, with 67.2% (95% CI, 67.04–67.37) achieving blood pressure control (<140/90 mmHg), and 36.8% (95% CI, 36.62–36.96) achieving strict control (<130/80 mmHg). For those with sub-optimal control, 63% had timely clinical follow-up and 48% underwent treatment intensification. A high proportion of individuals presented high risk features including obesity (36.4%; 95%CI, 36.2–36.5), diabetes (48.7%; 95%CI, 48.5–48.8) or high cardiovascular risk characteristics (81.7%, 95%IC, 81.5–81.8). Conclusion: Transforming routinely collected clinical data into an integrative monitoring platform is feasible within a newly federalised public health care provider. Routine monitoring of relevant indicators across multiple dimensions of care provides a structured basis for system-level oversight, longitudinal assessment, data-informed decision-making, and continuous learning within large public service delivery systems.
- 27 August 2026
- Published by SAGE Publications in Health Services Insights
- Vol. 19
Open AccessIntegrative Monitoring of Hypertension Care Using Routinely Collected Clinical Data in Mexico’s Emerging Federalised Public Health Care Provider
Background: Health information systems are a cornerstone for assessing health system performance, particularly for leading conditions contributing to disease burden, such as hypertension, making effective monitoring indispensable. In October 2023, Mexico initiated the federalisation of public health services for the population without social security, creating an integrated national public health care provider and increasing the need for system-level monitoring tools capable of supporting longitudinal assessment across heterogeneous settings. Objective: To describe the development and early application of an integrative monitoring platform using routinely collected clinical data to support system-level oversight of hypertension care within Mexico’s federalised public health care provider. Design: Descriptive health services research study based on secondary analysis of routinely collected clinical data. Methods: An integrative monitoring platform was developed to organise data into a structured indicator framework covering four domains: care engagement and continuity; clinical care processes; intermediate clinical outcomes; and case-mix and clinical complexity. The platform enables longitudinal and subnational analyses across selected indicators presented as illustrative use cases. Institutional reach was assessed using an overall monitoring period from January 2024 to September 2025, while clinical process and intermediate outcome indicators, including blood pressure control, were calculated within a predefined active six-month monitoring cohort using the September 2025 reporting date. Results: From January 2024 to September 2025, a total of 486,044 individuals received hypertension-related care within primary care services across participating states. The active six-month cohort included 322,661 individuals, with 67.2% (95% CI, 67.04–67.37) achieving blood pressure control (<140/90 mmHg), and 36.8% (95% CI, 36.62–36.96) achieving strict control (<130/80 mmHg). For those with sub-optimal control, 63% had timely clinical follow-up and 48% underwent treatment intensification. A high proportion of individuals presented high risk features including obesity (36.4%; 95%CI, 36.2–36.5), diabetes (48.7%; 95%CI, 48.5–48.8) or high cardiovascular risk characteristics (81.7%, 95%IC, 81.5–81.8). Conclusion: Transforming routinely collected clinical data into an integrative monitoring platform is feasible within a newly federalised public health care provider. Routine monitoring of relevant indicators across multiple dimensions of care provides a structured basis for system-level oversight, longitudinal assessment, data-informed decision-making, and continuous learning within large public service delivery systems.
- Open Access
- 18 April 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (4) , 100585
Integrating MASLD detection into diabetes care in primary care settings in Mexico: A cascade analysis
- 18 April 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (4) , 100585
Open AccessIntegrating MASLD detection into diabetes care in primary care settings in Mexico: A cascade analysis
- Open Access
- 2 January 2026
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 92 (1) , 111
Integrated Cardiovascular–Kidney–Metabolic Disease Burden in Mexico: Trends from 2000 to 2023 and Projections to 2050
Background: Cardiovascular–kidney–metabolic (CKM)‑related diseases are interconnected, yet their collective burden in Mexico remains unquantified. Objective(s): To quantify the magnitude, composition, temporal trends, geographic divergence, and projected trajectory of CKM‑related disease burden in Mexico. Methods: We analyzed Global Burden of Disease 2023 estimates of CKM‑related burden among Mexican adults aged 20 years or older; standard all‑age age‑standardized rates were used for comparisons with Latin America and the Caribbean and globally. Mutually exclusive causes were grouped into cardiovascular, kidney, type 2 diabetes, and metabolic dysfunction‑associated steatotic liver disease domains. We quantified disability‑adjusted life‑years (DALYs) during 2000–2023 and used 1990–2023 time series to project absolute burden and age‑standardized rates to 2050. Findings: CKM‑related DALYs increased from 3.82 million in 2000 to 8.71 million in 2023 (128%), and their share of all‑cause DALYs rose from 20.2% to 25.0%. In 2023, premature mortality accounted for 76.8% of the burden; cardiovascular disease and type 2 diabetes together accounted for 88.4%, with diabetes predominating among adults aged 40–64 years. Mexico’s age‑standardized DALY rate increased by 2.9% during 2000–2023, whereas rates declined by 16.1% in Latin America and the Caribbean and by 24.1% globally. Absolute DALYs are projected to reach 21.40 million by 2050 (95% prediction interval 19.27–23.77), while the age‑standardized rate remains broadly unchanged. Conclusions: Mexico has diverged from declining regional and global trends in age‑standardized CKM‑related burden. Persistent premature mortality, substantial diabetes burden during working age, and projected growth in absolute health loss support accelerated, coordinated public health and health‑system action across the CKM continuum.
- 2 January 2026
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 92 (1) , 111
Open AccessIntegrated Cardiovascular–Kidney–Metabolic Disease Burden in Mexico: Trends from 2000 to 2023 and Projections to 2050
Background: Cardiovascular–kidney–metabolic (CKM)‑related diseases are interconnected, yet their collective burden in Mexico remains unquantified. Objective(s): To quantify the magnitude, composition, temporal trends, geographic divergence, and projected trajectory of CKM‑related disease burden in Mexico. Methods: We analyzed Global Burden of Disease 2023 estimates of CKM‑related burden among Mexican adults aged 20 years or older; standard all‑age age‑standardized rates were used for comparisons with Latin America and the Caribbean and globally. Mutually exclusive causes were grouped into cardiovascular, kidney, type 2 diabetes, and metabolic dysfunction‑associated steatotic liver disease domains. We quantified disability‑adjusted life‑years (DALYs) during 2000–2023 and used 1990–2023 time series to project absolute burden and age‑standardized rates to 2050. Findings: CKM‑related DALYs increased from 3.82 million in 2000 to 8.71 million in 2023 (128%), and their share of all‑cause DALYs rose from 20.2% to 25.0%. In 2023, premature mortality accounted for 76.8% of the burden; cardiovascular disease and type 2 diabetes together accounted for 88.4%, with diabetes predominating among adults aged 40–64 years. Mexico’s age‑standardized DALY rate increased by 2.9% during 2000–2023, whereas rates declined by 16.1% in Latin America and the Caribbean and by 24.1% globally. Absolute DALYs are projected to reach 21.40 million by 2050 (95% prediction interval 19.27–23.77), while the age‑standardized rate remains broadly unchanged. Conclusions: Mexico has diverged from declining regional and global trends in age‑standardized CKM‑related burden. Persistent premature mortality, substantial diabetes burden during working age, and projected growth in absolute health loss support accelerated, coordinated public health and health‑system action across the CKM continuum.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Hypertension
- Vol. 2026 (1)
Uncontrolled Hypertension in Cardio‐Renal‐Metabolic Diseases: Real‐World Insights on Patient Profiles and Management Patterns From iCaReMe Global Registry
Background: Hypertension (HTN) is a leading risk factor for cardiovascular (CV) and renal morbidity and mortality, yet blood pressure (BP) control remains suboptimal worldwide. Understanding management patterns, especially among patients with coexisting Type 2 diabetes mellitus (T2DM), chronic kidney diseases (CKDs), or heart failure (HF), and assessing uncontrolled HTN burden across diverse health systems are critical to inform guideline‐concordant strategies to improve care. Methods: Cross‐sectional analysis includes participants with HTN, with or without comorbid T2DM, CKD, or HF enrolled in iCaReMe Global Registry across 29 countries. Demographic and clinical characteristics, antihypertensive treatment patterns, prevalence of uncontrolled HTN (defined as SBP ≥ 130 mmHg or DBP ≥ 80 mmHg), and its associated factors were assessed. Results: Among 23,063 participants, comorbidities included T2DM (71.4%), CKD (38.2%), and HF (14.6%). Key CV risk factors were family history of CV disease (34.3%), obesity (40.5%), and dyslipidemia (51.0%). Echocardiography (available in 28.6%) revealed left ventricular hypertrophy (LVH) in 30.6% and diastolic dysfunction in 42.4%. Overall, 88.7% were prescribed antihypertensive drugs: renin–angiotensin system (RAS) blockers (76.6%), calcium channel blockers (CCBs, 42.0%), beta‐blockers (41.4%), diuretics (23.7%), with a majority (62.3%) on combination regimens. Uncontrolled HTN was prevalent in 75.4%, who were younger (59.8 vs 61.8 years) and exhibited higher burden of obesity (42.5% vs 34.6%), CKD (39.3% vs 33.1%), LVH (32.9% vs 24.8%), and treated less intensively with antihypertensives (60.2% vs 88.7%) and combinations (46.2% vs 61.8%) when compared to the controlled HTN group. Multivariate analysis confirmed independent association of non‐use of RAS blockers/CCB/diuretics combinations (dual/triple therapy), obesity, and comorbid CKD, with uncontrolled HTN (OR [95% CI], 2.8 [2.44–3.18]/2.3 [1.66–3.16], 1.5 [1.38–1.65], and 1.4 [1.27–1.53], respectively, p < 0.0001). Conclusion: This study uncovers alarming rates of uncontrolled HTN in real‐world settings, exacerbated by comorbid T2DM/CKD/HF, underscoring the need to identify HTN management gaps and tailor innovative strategies to mitigate CV risk. Trial Registration: ClinicalTrials.gov identifier: NCT03549754
- 1 January 2026
- Published by Wiley in International Journal of Hypertension
- Vol. 2026 (1)
Open AccessUncontrolled Hypertension in Cardio‐Renal‐Metabolic Diseases: Real‐World Insights on Patient Profiles and Management Patterns From iCaReMe Global Registry
Background: Hypertension (HTN) is a leading risk factor for cardiovascular (CV) and renal morbidity and mortality, yet blood pressure (BP) control remains suboptimal worldwide. Understanding management patterns, especially among patients with coexisting Type 2 diabetes mellitus (T2DM), chronic kidney diseases (CKDs), or heart failure (HF), and assessing uncontrolled HTN burden across diverse health systems are critical to inform guideline‐concordant strategies to improve care. Methods: Cross‐sectional analysis includes participants with HTN, with or without comorbid T2DM, CKD, or HF enrolled in iCaReMe Global Registry across 29 countries. Demographic and clinical characteristics, antihypertensive treatment patterns, prevalence of uncontrolled HTN (defined as SBP ≥ 130 mmHg or DBP ≥ 80 mmHg), and its associated factors were assessed. Results: Among 23,063 participants, comorbidities included T2DM (71.4%), CKD (38.2%), and HF (14.6%). Key CV risk factors were family history of CV disease (34.3%), obesity (40.5%), and dyslipidemia (51.0%). Echocardiography (available in 28.6%) revealed left ventricular hypertrophy (LVH) in 30.6% and diastolic dysfunction in 42.4%. Overall, 88.7% were prescribed antihypertensive drugs: renin–angiotensin system (RAS) blockers (76.6%), calcium channel blockers (CCBs, 42.0%), beta‐blockers (41.4%), diuretics (23.7%), with a majority (62.3%) on combination regimens. Uncontrolled HTN was prevalent in 75.4%, who were younger (59.8 vs 61.8 years) and exhibited higher burden of obesity (42.5% vs 34.6%), CKD (39.3% vs 33.1%), LVH (32.9% vs 24.8%), and treated less intensively with antihypertensives (60.2% vs 88.7%) and combinations (46.2% vs 61.8%) when compared to the controlled HTN group. Multivariate analysis confirmed independent association of non‐use of RAS blockers/CCB/diuretics combinations (dual/triple therapy), obesity, and comorbid CKD, with uncontrolled HTN (OR [95% CI], 2.8 [2.44–3.18]/2.3 [1.66–3.16], 1.5 [1.38–1.65], and 1.4 [1.27–1.53], respectively, p < 0.0001). Conclusion: This study uncovers alarming rates of uncontrolled HTN in real‐world settings, exacerbated by comorbid T2DM/CKD/HF, underscoring the need to identify HTN management gaps and tailor innovative strategies to mitigate CV risk. Trial Registration: ClinicalTrials.gov identifier: NCT03549754
- Open Access
- 5 April 2025
- Published by Elsevier in Clinical Medicine
- Vol. 25 (3) , 100310
Exploring prediabetes remission in public primary care in Mexico: A cascade analysis
- 5 April 2025
- Published by Elsevier in Clinical Medicine
- Vol. 25 (3) , 100310
Open AccessExploring prediabetes remission in public primary care in Mexico: A cascade analysis
- Open Access
- 22 March 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1253492
External validation of a minimal-resource model to predict reduced estimated glomerular filtration rate in people with type 2 diabetes without diagnosis of chronic kidney disease in Mexico: a comparison between country-level and regional performance
Background: Patients with type 2 diabetes are at an increased risk of chronic kidney disease (CKD) hence it is recommended that they receive annual CKD screening. The huge burden of diabetes in Mexico and limited screening resource mean that CKD screening is underperformed. Consequently, patients often have a late diagnosis of CKD. A regional minimal-resource model to support risk-tailored CKD screening in patients with type 2 diabetes has been developed and globally validated. However, population heath and care services between countries within a region are expected to differ. The aim of this study was to evaluate the performance of the model within Mexico and compare this with the performance demonstrated within the Americas in the global validation.Methods: We performed a retrospective observational study with data from primary care (Clinic Specialized in Diabetes Management in Mexico City), tertiary care (Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán) and the Mexican national survey of health and nutrition (ENSANUT-MC 2016). We applied the minimal-resource model across the datasets and evaluated model performance metrics, with the primary interest in the sensitivity and increase in the positive predictive value (PPV) compared to a screen-everyone approach.Results: The model was evaluated on 2510 patients from Mexico (primary care: 1358, tertiary care: 735, ENSANUT-MC: 417). Across the Mexico data, the sensitivity was 0.730 (95% CI: 0.689 – 0.779) and the relative increase in PPV was 61.0% (95% CI: 52.1% - 70.8%). These were not statistically different to the regional performance metrics for the Americas (sensitivity: p=0.964; relative improvement: p=0.132), however considerable variability was observed across the data sources.Conclusion: The minimal-resource model performs consistently in a representative Mexican population sample compared with the Americas regional performance. In primary care settings where screening is underperformed and access to laboratory testing is limited, the model can act as a risk-tailored CKD screening solution, directing screening resources to patients who are at highest risk.
- 22 March 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1253492
Open AccessExternal validation of a minimal-resource model to predict reduced estimated glomerular filtration rate in people with type 2 diabetes without diagnosis of chronic kidney disease in Mexico: a comparison between country-level and regional performance
Background: Patients with type 2 diabetes are at an increased risk of chronic kidney disease (CKD) hence it is recommended that they receive annual CKD screening. The huge burden of diabetes in Mexico and limited screening resource mean that CKD screening is underperformed. Consequently, patients often have a late diagnosis of CKD. A regional minimal-resource model to support risk-tailored CKD screening in patients with type 2 diabetes has been developed and globally validated. However, population heath and care services between countries within a region are expected to differ. The aim of this study was to evaluate the performance of the model within Mexico and compare this with the performance demonstrated within the Americas in the global validation.Methods: We performed a retrospective observational study with data from primary care (Clinic Specialized in Diabetes Management in Mexico City), tertiary care (Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán) and the Mexican national survey of health and nutrition (ENSANUT-MC 2016). We applied the minimal-resource model across the datasets and evaluated model performance metrics, with the primary interest in the sensitivity and increase in the positive predictive value (PPV) compared to a screen-everyone approach.Results: The model was evaluated on 2510 patients from Mexico (primary care: 1358, tertiary care: 735, ENSANUT-MC: 417). Across the Mexico data, the sensitivity was 0.730 (95% CI: 0.689 – 0.779) and the relative increase in PPV was 61.0% (95% CI: 52.1% - 70.8%). These were not statistically different to the regional performance metrics for the Americas (sensitivity: p=0.964; relative improvement: p=0.132), however considerable variability was observed across the data sources.Conclusion: The minimal-resource model performs consistently in a representative Mexican population sample compared with the Americas regional performance. In primary care settings where screening is underperformed and access to laboratory testing is limited, the model can act as a risk-tailored CKD screening solution, directing screening resources to patients who are at highest risk.
- Open Access
- 18 October 2023
- Published by Elsevier in Diabetes Epidemiology and Management
- Vol. 13
Diabetic retinopathy prevalence in Mexico: Results from a primary public health access initiative for screening in patients with type 2 diabetes
- 18 October 2023
- Published by Elsevier in Diabetes Epidemiology and Management
- Vol. 13
Open AccessDiabetic retinopathy prevalence in Mexico: Results from a primary public health access initiative for screening in patients with type 2 diabetes
- 26 August 2023
- Published by Elsevier in Primary Care Diabetes
- Vol. 17 (6) , 568-574
Impact of a multicomponent integrated care delivery program on diabetes care goals achievement: a primary care quality improvement initiative
- 26 August 2023
- Published by Elsevier in Primary Care Diabetes
- Vol. 17 (6) , 568-574
Impact of a multicomponent integrated care delivery program on diabetes care goals achievement: a primary care quality improvement initiative
- 17 September 2022
- Published by Elsevier in Primary Care Diabetes
- Vol. 16 (6) , 780-785
Adherence to antidiabetic treatment in primary health care in individuals with type 2 diabetes. A survey including socio-demographic, patient related and clinical factors
- 17 September 2022
- Published by Elsevier in Primary Care Diabetes
- Vol. 16 (6) , 780-785
Adherence to antidiabetic treatment in primary health care in individuals with type 2 diabetes. A survey including socio-demographic, patient related and clinical factors